Blood cancer charities have welcomed decisions to extend the use of a targeted antibody for treating multiple myeloma within the NHS in England and Wales.
According to new guidance from the National Institute for Health and Care Excellence (NICE), the drug, teclistamab, can now be given to adults with relapsed or refractory disease. They must have had at least three lines of treatment, including an immunomodulatory drug, a proteosome inhibitor, and an anti-CD38 antibody.
This will extend availability of the drug to about 700 people, NICE said in its final guidance.
In the initial draft guidance, NICE had proposed to restrict the drug only to being an alternative to pomalidomide with dexamethasone. Campaigners from Myeloma UK and Blood Ca...
20 hours ago
